About Varmx
Varmx is a company based in Leiden (Netherlands) founded in 2015 by Pieter H Reitsma. Varmx has raised $77.19 million across 8 funding rounds from investors including EQT, European Commission and Rijksdienst voor Ondernemend Nederland. Varmx offers products and services including VMX-C001. Varmx operates in a competitive market with competitors including Hemab, AbFero Pharmaceuticals, Alveron Pharma, TargED and Pangen Biotech, among others.
- Headquarter Leiden, Netherlands
- Founders Pieter H Reitsma
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Varmx B.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$77.19 M (USD)
in 8 rounds
-
Latest Funding Round
$32.3 M (USD), Series B
May 25, 2023
-
Investors
EQT
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Varmx
Varmx offers a comprehensive portfolio of products and services, including VMX-C001.
Restores coagulation to manage bleeding in FXa-DOAC patients effectively.
People of Varmx
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Varmx
Varmx has successfully raised a total of $77.19M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $32.3 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Varmx
Varmx has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, European Commission and Rijksdienst voor Ondernemend Nederland.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked | |
|
Early & late stage VC firm investing primarily in Netherlands
|
Locked | Locked | Locked |
Investor details for Varmx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Varmx
Investment portfolio details for Varmx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Varmx
Detailed financials for Varmx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Varmx Comparisons
Peer comparison for Varmx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Varmx
Varmx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemab, AbFero Pharmaceuticals, Alveron Pharma, TargED and Pangen Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Preventative therapies for rare bleeding and thrombotic disorders are developed.
|
|
| Locked | Locked | Locked |
Oral iron chelators are developed for iron overload disease treatment.
|
|
| Locked | Locked | Locked |
Drugs for haemorrhagic stroke and intracranial haemorrhage are developed.
|
|
| Locked | Locked | Locked |
Biological drugs for thrombosis treatment are developed by the company.
|
|
| Locked | Locked | Locked |
Developer of biosimilars and biologics
|
Detailed competitors of Varmx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Varmx
Complete news archive for Varmx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Varmx
Varmx was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Varmx is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Varmx is a funded company, having raised a total of $77.19M across 8 funding rounds to date.
VarmX, a spin-out company from the Leiden University Medical Center, is focussed on development and manufacturing of therapeutic proteins to restore blood clotting in bleeding patients. Its lead product PseudoXa is a modified recombinant human coagulation factor X and is being developed to restore blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. DOACS are taken by patients for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs.
Varmx's top competitors include Hemab, Cadrenal Therapeutics and Alveron Pharma.
Varmx offers VMX-C001.
Varmx has 14 investors. Key investors include EQT, European Commission, Rijksdienst voor Ondernemend Nederland, European Union, and Life Sciences Partners.